Continuous Glucose Monitoring Device Market Size, Share, Trends & Forecast, 2026–2034
REPORT DETAILS
Continuous Glucose Monitoring Device Market Summary
The continuous glucose monitoring devices market size was valued at USD 13.73 billion in 2025. The market is projected to register a CAGR of 15.5% from 2026 to 2034. The continuous glucose monitoring device market is growing rapidly, driven by rising diabetes prevalence, technological advancements in sensor accuracy, supportive government policies, and increasing integration with digital health platforms, which enhance real-time monitoring, patient engagement, and overall disease management.
Market Statistics
Key Takeaways
- North America held the largest CGM market share of 41.28% in 2025. High diabetes prevalence and advanced healthcare systems boost the dominance.
- Asia Pacific is projected to witness rapid growth at a 15.42% CAGR. Rising diabetes cases and increasing healthcare expenditure drive the regional market growth.
- The sensors segment led with a 48.63% market share in 2025. The segment’s dominance is driven by improved accuracy and longer sensor life.
- The transmitters & receivers segment is projected to witness the fastest growth at a 16.18% CAGR. Innovation in wireless technologies drives the market’s growth. Also, rising requirements for real-time transmission of glucose information to smartphones and insulin pumps fuel the expansion.
- The Bluetooth segment led with a 72.45% revenue share in 2025. Widespread smartphone integration and seamless data syncing drive the segment’s dominance.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What is a continuous glucose monitor?
A continuous glucose monitoring (CGM) device is a type of wearable medical equipment, which allows users to measure their glucose levels in the interstitial fluid on a continuous basis via a tiny sensor that is placed via a tiny sensor inserted just beneath the skin (subcutaneously), with a transmitter worn on the skin's surface. It offers real-time glucose values, trends, and alerts, and users can track changes without relying on repeated finger-stick tests.
The continuous glucose monitoring market growth rate is expected to rise in the forecast period due to the high incidence of diabetes and growing preference for real-time blood glucose monitoring devices. For instance, an estimated 2.1 million people in the U.S. have been diagnosed with type 1 diabetes, including 1.8 million adults aged 20 years and above and 314,000 children and adolescents under 20. Increasing demand for home-based diabetes management and personalized digital health solutions is also boosting the market growth (Source: www.cdc.gov).
How Does a CGM Device Work?
- A wearable sensor is placed under the skin to measure glucose levels.
- The glucose biosensor technology monitors glucose levels every 1–5 minutes.
- Readings are transmitted wirelessly to a receiver or smartphone.
- The devices display real-time glucose values and trend graphs.
- Users receive notification of alerts in case of high or low glucose levels.
- Many CGM systems require little or no fingerstick calibration.
CGM vs. Traditional Blood Glucose Monitoring
| Parameter | Continuous Glucose Monitoring (CGM) | Conventional Fingerstick Testing |
| Method | Continuous, real-time monitoring | Single-point testing |
| Availability | 24/7 glucose trends and notifications | Notifications only when tested |
| User Convenience | Minimal finger pricking | Frequent finger pricking is needed |
| Notifications | High/Low glucose notifications | Notifications not available |
| Trending | Monitoring of glucose trend patterns | Past history is limited |
| Connectivity | Integration with smartphone & cloud | Standalone glucometers |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
AI Impact on Continuous Glucose Monitoring Device Market
- AI aids in improving real-time glucose pattern analysis for continuous glucose monitors.
- AI assists in detecting glucose variations at an early stage for managing diabetes better.
- AI helps in gaining personal insights from user data for alerting users accordingly.
- It facilitates the monitoring and treatment of patients using predictive analytics and data collection tools.
Continuous Glucose Monitoring Device Market Dynamics
Driver: Rising Prevalence of Diabetes
The increasing prevalence of diabetes around the world is greatly raising the demand for glucose monitoring devices, especially for continuous glucose monitoring (CGM) systems. CGM systems allow for real-time management of the disease. The International Diabetes Federation (IDF) Diabetes Atlas 2025 states that about 589 million adults between the ages of 20 and 79 years (i.e., one in every nine adults worldwide) have diabetes. This number is expected to rise to 853 million by 2050. Furthermore, nearly 252 million adults still remain undiagnosed. This underscores the need for early detection and for diabetes devices. There is a growing burden of the disease and the increasing awareness of the importance of diabetes management and the prevention of complications. Thus, the use of advanced glucose monitoring technologies is being speeded up in healthcare settings (Source: diabetesatlas.org).
Driver: Government Initiatives and Healthcare Policies
Government support measures and health policies are crucial for increasing access to glucose monitoring equipment and for speeding up market growth. In the United States, the Centers for Medicare & Medicaid Services (CMS) has broadened the Medicare Part B coverage to include therapeutic continuous glucose monitoring (CGM) devices. Eligible people who have diabetes and who either use insulin or have a past history of severe hypoglycemia can now get reimbursement for CGM devices and the associated supplies. Moreover, CMS mandates that standardized coding verification be carried out for CGM products that are covered. This enhances clarity regarding reimbursement and facilitates market access for devices that have been approved. Because of these reimbursement policies, patients have lower out-of-pocket expenses. Thus, they are more likely to adopt advanced glucose monitoring technologies. Also, there is a rising use of CGMs that are better integrated into regular diabetes management (Source: cms.gov).
Opportunity: Technological Advancements in Glucose Monitoring
Technological advancements in continuous glucose monitoring are driving CGM device market growth. Advanced devices offer improved accuracy and user convenience. Today's devices send real-time data to smartphones and other digital systems. It enables proactive management of diabetes. Contemporary CGM systems generally have a Mean Absolute Relative Difference (MARD) accuracy. It ranges from 8% to 11%, thus increasing the reliability of glucose readings. The duration for which the sensor can be worn has also been extended to 14 to 15 days. It reduces the need for frequent replacements and makes use of greater convenience. In addition, predictive alerts based on AI enable the identification of impending high or low glucose levels. These alerts allow for timely action and more effective management of diabetes. Further advances in the wider use of these devices are due to innovations such as sensors that last longer and the fact that non-invasive monitoring methods are available.
Restraint: Inconsistent Reimbursement Policies
Reimbursement policies differ from country to country and between insurance companies, which slows down the uptake of glucose monitoring devices, especially continuous glucose monitoring (CGM) systems. In many developed markets, support for reimbursement has been broadened. Nevertheless, the conditions for coverage, the need for prior authorization, and the reimbursement criteria vary between public and private payers. For example, U.S. Medicare has specific eligibility conditions and durability medical equipment (DME) coverage criteria if CGM is to be reimbursed. In contrast, coverage for some devices and supplies may be refused if these requirements are not fulfilled. These differences in reimbursement lead to higher out-of-pocket costs. They delay patient access to advanced glucose monitoring technologies. These aspects limit broader market penetration.
Digital Diabetes Management Ecosystem
Digital diabetes management ecosystem involves the integration of CGM devices with insulin delivery systems, mobile applications, wearables, digital therapeutics, telehealth platforms, and AI-powered data analysis tools. These solutions offer personalized insights and automatic alerts. Patients get real-time blood sugar readings via smartphone apps or wearables. Cloud-based telemedicine platforms enable healthcare professionals to treat patients remotely. The use of AI-powered technology provides information on glucose level fluctuations. Healthcare professionals can make necessary decisions based on this information. Adoption of such innovation leads to improved diabetes management.
Source: Polaris Market Research Analysis
Continuous Glucose Monitoring Device Market Segment Insights
Component Type-Based Insights
The continuous glucose monitoring device market, by component type, is segmented into transmitters & receivers, sensors, and insulin pumps. The sensors segment led with a 48.63% market share in 2025. This dominance is attributed to technological advancements that have led to the development of smaller, more accurate, and longer-lasting sensors, enhancing user comfort and convenience. These improvements have made sensors integral to continuous glucose monitoring systems, as they provide real-time data on glucose levels, facilitating better diabetes management.
The transmitters & receivers segment is projected to witness the fastest growth at a 16.18% CAGR. Transmitters play a crucial role in continuous glucose monitoring devices by wirelessly communicating data from the sensor to external devices such as receivers or smartphones. The increasing demand for real-time glucose monitoring and the integration of continuous glucose monitoring data with digital health platforms contribute to the rapid growth of the transmitters segment.
Indication Insights-Based Insights
In terms of indication, the market is bifurcated into type 1 diabetes and type 2 diabetes. The Type 1 Diabetes segment led with a larger market share. This is due to the lifelong requirement for intensive glucose monitoring and insulin therapy. Individuals affected by Type 1 diabetes require frequent glucose monitoring. This helps prevent hypoglycemia and hyperglycemia. Thus, CGMs are becoming an essential part of daily disease management. Adoption of automated insulin delivery systems and sensor-integrated insulin pumps is rising. It strengthens demand in this segment. Favorable reimbursement policies in several developed markets support higher CGM penetration among Type 1 diabetes patients.
The Type 2 Diabetes segment is expected to register a higher CAGR during the forecast period. Rising diabetes prevalence and increasing obesity rates fuel the demand for CGM for type 2 diabetes management. Also, greater awareness of continuous glucose monitoring benefits boosts the adoption beyond insulin-dependent patients. Healthcare providers are increasingly recommending CGMs to improve glycemic control, treatment adherence, and long-term disease management. Expanding insurance coverage and growing use of digital health platforms would accelerate segment growth.
Comparison Matrix: Type 1 Diabetes vs. Type 2 Diabetes
| Parameter | Type 1 Diabetes | Type 2 Diabetes |
| Patient Population | Smaller | Largest patient population |
| Monitoring Frequency | Continuous and intensive | Moderate to continuous, depending on therapy |
| Primary Device Demand | CGMs and insulin pump integration | CGMs and blood glucose meters |
| Key Growth Driver | Lifelong insulin dependence | Rising diabetes prevalence and obesity |
| Technology Adoption | High adoption of automated insulin delivery | Increasing adoption for improved glycemic control |
| Reimbursement Impact | Strong support in developed markets | Expanding coverage across multiple healthcare systems |
| Growth Outlook | Stable, high-value segment | Fast-growing, high-volume segment |
Source: Polaris Market Research Analysis
Connectivity-Based Insights
The continuous glucose monitoring device market, by connectivity, is segmented into Bluetooth and 4G. The Bluetooth segment led with a 72.45% revenue share in 2025. This prominence is attributed to Bluetooth's widespread compatibility and user-friendly nature, enabling seamless integration with smartphones and other devices. For instance, the Dexcom G6 CGM system utilizes Bluetooth to transmit glucose data to compatible devices every five minutes, providing users with real-time monitoring capabilities.
The 4G connectivity segment is experiencing the fastest growth rate within the market. Sensors equipped with 4G connectivity facilitate real-time data transmission to healthcare providers, allowing for prompt feedback on glucose levels. This advancement enables patients to make necessary adjustments to their insulin dosage or diet plan based on the received information, thereby enhancing diabetes management.
End Use-Based Insights
The continuous glucose monitoring device market, by end use, is segmented into hospitals, homecare diagnostics, and others. The homecare diagnostics segment holds the largest revenue share. This prominence is attributed to the increasing preference for personal health management and the convenience of monitoring glucose levels outside clinical settings. Continuous glucose monitoring devices designed for home use empower patients to manage their diabetes more effectively, leading to improved adherence to treatment plans and better health outcomes. The accessibility and user-friendly nature of these devices have significantly contributed to their widespread adoption in homecare settings.
The hospital segment is experiencing the highest growth rate within the market. This surge is driven by the rising number of hospital visits for diabetes management and the increasing utilization of continuous glucose monitoring devices in inpatient care. Hospitals are integrating these devices into their treatment protocols to provide real-time glucose monitoring, which aids in timely decision-making and enhances patient care. The ability of continuous glucose monitoring devices to deliver continuous data on glucose levels is particularly beneficial in critical care settings, contributing to their growing adoption in hospitals.
Distribution Channel Insights
The pharmacy sector is anticipated to account for the largest share 59.4% of the market by 2025. This is attributed to their availability, trusted position in chronic disease management, and new business models that facilitate the sale of prescription and over-the-counter (OTC) glucose monitors. Alliances between CGM producers and national pharmacy chains also solidify the dominance in the market. For instance, DexCom, Inc. and Abbott have established partnerships with CVS Health, Walgreens, and Walmart to make their devices available in-store and through online prescription services.
Source: Polaris Market Research Analysis
Real-World Use Cases of CGM Devices
-
Type 1 Diabetes: CGMs allow for accurate insulin dosing based on glucose trends in real time and decrease the risk of hypoglycemia/hyperglycemia. In the U.S., data from the CDC indicate that 2.1 million have diagnosed type 1 diabetes, and 314,000 of those are children, which has fueled strong CGM adoption for the daily management of insulin (Source: cdc.gov).
-
Sleep Hypoglycemia Alerts: CGM systems can monitor glucose levels while someone sleeps. The systems send alerts when glucose levels are approaching or reach hypoglycemic ranges. The alerts that occur during the night can help enable a timely response. It decreases the chances of having prolonged nocturnal hypoglycemia.
-
Gestational Diabetes: Glucose monitoring allows pregnant women to keep track of changes in their glucose levels without having to carry out frequent finger-pricks. The CDC reports that between 5 and 9 out of every 100 pregnant women in the U.S. are affected by gestational diabetes each year. Thus, there is a growing need for continuous monitoring in prenatal care guidelines (Source: cdc.gov).
Key Areas of CGM Devices Market
- Wearable Health Device & Digital Health Ecosystem Integration: Wearable health devices can be integrated with digital health platforms. The integration leads to continuous, connected diabetes care. CGM devices send glucose readings to smartphones, smartwatches, and mobile apps. Patients and doctors can monitor glucose patterns remotely. This way, integration with digital health ecosystems supports remote patient monitoring. It also helps in personalized treatment management.
- Closed-Loop Insulin Systems (Artificial Pancreas System): Closed-loop insulin systems link CGM technology to insulin pumps together with automated algorithms. They modify insulin delivery according to changing glucose levels. MiniMed 780G with SmartGuard can automatically adjust the basal insulin. Correction doses are given based on the CGM readings. The Tandem Control-IQ+ system uses predictive algorithms to increase, decrease, or suspend insulin delivery when it anticipates glucose fluctuations. The increasing integration of CGMs with automated insulin delivery is leading to better time-in-range results. It is decreasing the need for manual action. This is helping to meet the demand for more advanced glucose monitoring technologies.
- Non-Diabetic & Wellness Applications: Beyond conventional methods, the use of glucose monitoring is rising in wellness, metabolic health, and lifestyle. For instance, Abbott Lingo features a biosensor together with a mobile application, giving users real-time glucose insights. The app provides personalized coaching covering nutrition, metabolism, and general well-being. The move into non-diabetic and wellness applications will create opportunities for CGM manufacturers and will increase the number of consumers who can use their products.
Regional Insights
North America CGM Devices Market
By region, the study covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the largest CGM market share of 41.28% in 2025 of the continuous glucose monitoring device market revenue, primarily due to the high prevalence of diabetes, well-established healthcare infrastructure, and strong reimbursement policies that support CGM adoption. The region benefits from significant investments in technological advancements, early regulatory approvals, and a strong presence of key market players driving innovation. Additionally, growing awareness among individuals regarding proactive diabetes management and increasing integration of CGM devices with digital health platforms further support market growth. While North America leads, other regions such as Asia Pacific are experiencing rapid expansion due to rising diabetes cases, improving healthcare accessibility, and growing adoption of advanced glucose monitoring solutions.
Europe CGM Devices Market
The Europe continuous glucose monitoring device market is growing due to increasing diabetes prevalence, favorable reimbursement policies, and advancements in healthcare infrastructure. Countries such as Germany, the UK, and France are key contributors, driven by high adoption rates of CGM devices and strong government initiatives supporting diabetes management. The region benefits from a well-regulated medical device sector, ensuring the availability of innovative CGM solutions. Additionally, collaborations between healthcare providers and technology companies are enhancing remote monitoring and digital health integration, further boosting market expansion.
Asia Pacific CGM Devices Market
Asia Pacific is projected to witness rapid growth at a 15.42% CAGR is experiencing rapid growth due to rising diabetes cases, increasing healthcare expenditure, and improving awareness of advanced glucose monitoring solutions. Countries such as China, India, and Japan are leading this growth, supported by expanding healthcare infrastructure and government initiatives promoting diabetes care. The demand for cost-effective and non-invasive CGM devices is increasing as affordability and accessibility improve. Additionally, the region is witnessing a surge in telemedicine and digital health adoption, further accelerating CGM adoption in both urban and rural areas.
Continuous Glucose Monitoring Market in India
The growing diabetic population is driving the demand for CGM in India. According to the International Diabetes Federation. the number of people having diabetes is expected to increase to 123.5 million by 2040. Govt NCD programs (NP-NCD, under National Health Mission) are focusing more and more on now diabetes management, fostering awareness and diagnostic infrastructure. Increasing insulin consumption, urban lifestyle associated diabetes, and better healthcare access are driving CGM penetration beyond metros into tier-2 cities, making India one of the fastest growing CGM market globally (Source: www.icmr.gov.in).
Latin America CGM Devices Market
The Latin America continuous glucose monitoring devices market share is anticipated to be driven by the high incidence of diabetes, the growing penetration of advanced glucose monitoring solutions and increasing awareness level. Although historically access has been restricted due to cost and poor reimbursement coverage, urban populations in countries such as Brazil, Argentina, and Colombia are now beginning to see wider adoption of CGM devices, particularly among patients with Type 1 diabetes and insulin-dependent Type 2 cases.
The growth in Brazil is being propelled by its large diabetic population, a progressive regulatory environment, and an increasing private healthcare sector. The need for more accurate and continuous glucose monitoring systems is increasing with 16.6 million people diagnosed with diabetes. Several CGM systems of the type previously marketed in the U.S. have been approved by the Brazilian National Health Surveillance Agency (ANVISA), including those from Abbott and Medtronic, that can be used in the private sector and in certain cases through public health options (Source: idf.org).
MEA CGM Devices Market
The Middle East and Africa continuous glucose monitoring devices market is propelled by the increasing awareness regarding digital health solutions, the government initiatives towards the modernization of chronic disease management, and the escalating cases of diabetes. Diabetes prevalence is among the highest in the world in some parts of the Gulf region, such as in UAE, Saudi Arabia, and Qatar where CGM is gaining foothold due to high income population, developed healthcare system, and availability of private insurance.
Source: Polaris Market Research Analysis
Sustainability and Device Evolution
The concept of sustainability has been gaining momentum in the market for CGM devices as companies aim to minimize the environmental impact of wearable medical devices. They are developing sensors made of recyclable materials, using environmentally friendly packaging, and making their wearable devices more durable to minimize electronic waste from replacement sensors. Battery improvements, power-efficient wireless communication, and smaller device sizes are among the factors that help prolong device lifecycles while minimizing resource use. Moreover, the optimization of the production process and the minimization of single-use plastics are among the steps aimed at achieving healthcare sustainability goals.
Competitive Analysis
Several market players are actively contributing to advancements in diabetes management. Dexcom, Inc. provides solutions that allow for real-time glucose monitoring. Abbott Laboratories developed the FreeStyle Libre system. The system helps users track their glucose levels using a sensor. Medtronic plc combines CGM technology with insulin pump systems to improve overall diabetes care. Senseonics Holdings, Inc. has the Eversense CGM system. It includes an implantable sensor for use over extended periods. Ypsomed AG focuses on insulin delivery systems and has now entered the field of CGM technologies. A. Menarini Diagnostics S.r.l. supplies a variety of diagnostic solutions, such as CGM devices. GlySens Incorporated is working on implantable CGM systems for long-term monitoring. F. Hoffmann-La Roche Ltd. provides integrated diabetes management solutions, including CGM devices.
In the highly competitive market, businesses are working to improve the accuracy, ease of use, and cost-effectiveness of CGM devices. Recently, Dexcom and Abbott have launched OTC CGM with the intention of extending access to people who do not need insulin. Medtronic is still advancing its offerings by combining CGM technology with insulin delivery systems to provide full-range diabetes devices. Senseonics has developed an implantable sensor as a solution for those who want to wear the sensor for a longer period. At the same time, new companies such as Nemaura Medical are concentrating on non-invasive monitoring technologies, thus helping to increase the variety of CGM solutions available.
Vendor Landscape
| Company | Key CGM Product / Platform | Core Technology | Market Positioning |
| Abbott Laboratories | FreeStyle Libre portfolio | Sensor-based real-time continuous glucose monitoring with smartphone connectivity | Market Leader |
| DexCom, Inc. | Dexcom G7 / G7 15 Day | Wearable real-time CGM with automated glucose readings, alerts, and smart-device connectivity | Market Leader |
| Medtronic plc | Simplera, Simplera Sync, Guardian 4 | CGM integrated with insulin pump and diabetes-management systems | Leading Integrated Diabetes-Care Provider |
| Senseonics Holdings, Inc. | Eversense 365 / Eversense E3 | Long-term implantable CGM with removable smart transmitter and mobile application | Long-Term Implantable CGM Specialist |
| Menarini Diagnostics S.r.l. | GlucoMen Day CGM | Wearable continuous glucose monitoring sensor supported by reusable components and digital monitoring | Established Regional CGM Provider |
Source: Polaris Market Research Analysis
List of Key Companies
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- DexCom, Inc.
- F. Hoffmann-La Roche Ltd.
- GlySens Incorporated
- Medtronic plc
- Menarini Diagnostics S.r.l.
- Nemaura Medical Inc.
- Senseonics Holdings, Inc.
- Ypsomed AG
Industry Developments
- August 2026: Abbott announced a partnership with Google Health to redefine everyday health through glucose insights and artificial intelligence. The deal will emphasize integrating ongoing glucose insights from the Lingo continuous glucose monitor (CGM) into Google Health. It will help users understand how sleep, nutrition, activity, and stress affect their glucose levels. (Source: abbott.mediaroom.com)
- June 2026: FiberSense AG received CE marking for its FiberSense Continuous Glucose Monitoring (CGM) System under Regulation (EU) 2017/745 as a Class IIb medical device. (Source: PRNewswire)
- June 2026: The U.S. Food and Drug Administration cleared for marketing the Stelo Glucose Biosensor System by Dexcom Inc. The Stelo Glucose Biosensor System is an integrated CGM indicated for children and adolescents aged two years and older who do not use insulin. (Source: fda.gov)
- June 2026: Insulet Corporation announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The company also announced the compatibility of the system in the U.S. with Abbott’s Libre 3 Plus sensor. (Source: insulet.com)
- April 2025: F. Hoffmann-La Roche Ltd, a member of the Roche Group, announced the construction of a new continuous glucose monitoring (CGM) manufacturing site in Indiana. (Source: www.roche.com)
- June 2025: The U.S. Health Secretary announced that the Department of Health and Human Services would launch a major federal initiative. The initiative will promote the use of wearable health monitoring devices, including CGMs. It will help lower diabetes-related healthcare costs. It will encourage proactive self-monitoring and preventive care through wearables. (Source: www.reuters.com)
Future Outlook
From an analyst's point of view, the continuous glucose monitoring (CGM) device market will continue to grow with the increasing adoption of CGM in patients with Type 2 and in the preventive health space beyond insulin-dependent patients. The future market will be driven by longer-life sensors, higher accuracy, smaller wearable formats, and deeper integration with smartphones, insulin pumps, and AI-enabled analytics. Growing reimbursement coverage and home-based diabetes management will also contribute to the uptake. The manufacturers will likely concentrate on non-invasive or minimally invasive technologies, predictive glucose analytics, and interoperable digital ecosystems. Developing markets are also anticipated to present lucrative growth opportunities as awareness, affordability, and access to healthcare increase.
How is the report valuable for an organization?
Workflow/Innovation Strategy: The continuous glucose monitoring device market has been segmented into detailed segments of component type, connectivity, and end use. Moreover, the study provides the reader with a detailed understanding of the different segments at both the global and regional levels.
Growth/Marketing Strategy: Companies in the continuous glucose monitoring device market focus on expanding accessibility, technological advancements, and strategic partnerships to drive growth. Many manufacturers are investing in research and development to enhance sensor accuracy, extend wear duration, and integrate CGM systems with digital health platforms. Market players are also emphasizing direct-to-consumer sales and over-the-counter product launches to reach a broader audience. Collaborations with healthcare providers and insurance companies help improve adoption rates by ensuring better reimbursement options. Additionally, geographic expansion into emerging markets and regulatory approvals for new devices contribute to market growth.
Market Segmentation Outlook
By Component Type Outlook (Revenue – USD Billion, 2021–2034)
- Transmitters & Receivers
- Sensors
- Insulin Pumps
By Indication Outlook (Revenue – USD Billion, 2021–2034)
- Type 1 Diabetes
- Type 2 Diabetes
By Connectivity Outlook (Revenue – USD Billion, 2021–2034)
- Bluetooth
- 4G
By End Use Outlook (Revenue – USD Billion, 2021–2034)
- Hospitals
- Homecare Diagnostics
- Others
By Distribution Channel Outlook (Revenue – USD Billion, 2021–2034)
- Pharmacies
- E-commerce
- Other
By Regional Outlook (Revenue – USD Billion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 13.73 billion |
| Market Size Value in 2026 | USD 15.83 billion |
| Revenue Forecast by 2034 | USD 50.21 billion |
| CAGR | 15.5% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Continuous Glucose Monitoring Device Market FAQ's
The continuous glucose monitoring device market size was valued at USD 13.73 billion in 2025 and is projected to grow to USD 50.21 billion by 2034.
The market is projected to register a CAGR of 15.5% during the forecast period.
North America accounted for the largest market share of 41.28% in 2025, driven by the high prevalence of diabetes and well-established healthcare infrastructure.
Several companies are actively contributing to advancements in diabetes management. Dexcom, Inc. is renowned for its innovative CGM systems, offering real-time glucose monitoring solutions. Abbott Laboratories has developed the FreeStyle Libre system, providing users with a sensor-based approach to glucose tracking. Medtronic plc integrates CGM technology with insulin pump systems, enhancing comprehensive diabetes care.
The sensors segment accounted for the largest market share of 48.63%, driven by technological advancements that enable smaller, more accurate, and longer-lasting sensors.
The Bluetooth segment accounted for the largest market share of 72.45%, driven by Bluetooth's widespread compatibility and user-friendly nature.
A CGM is a wearable sensor that monitors interstitial glucose?at short intervals and transmits the data to a phone or a receiver. Glucometers require manual finger-pricks for single-point blood glucose readings.
A continuous glucose monitoring (CGM) device is a medical device that tracks blood glucose levels in real time throughout the day and night. It consists of a small sensor placed under the skin, which measures glucose levels in interstitial fluid and transmits the data to a receiver, smartphone, or insulin pump. Unlike traditional fingerstick tests, CGM devices provide continuous data, allowing users to monitor glucose trends and fluctuations more effectively. These devices are widely used for diabetes management, helping individuals make informed decisions about diet, medication, and lifestyle adjustments.
A few key trends in the market are described below: Integration with Digital Health Platforms – CGM devices are increasingly being integrated with mobile apps, smartwatches, and cloud-based platforms for real-time monitoring and data sharing with healthcare providers. Over-the-Counter (OTC) CGM Devices – Companies are launching non-prescription CGM devices to expand accessibility, particularly for individuals without insulin dependence. Advancements in Sensor Technology – Newer CGM sensors offer extended wear duration, improved accuracy, and reduced calibration requirements, enhancing user convenience. Rising Adoption of AI and Predictive Analytics – AI-powered algorithms are being integrated into CGM systems to analyze glucose trends and provide predictive insights for better diabetes management.
A new company entering the continuous glucose monitoring device market can focus on non-invasive CGM technology to differentiate itself from existing players and improve patient comfort. Investing in AI-driven predictive analytics can enhance glucose monitoring accuracy and provide proactive health insights. Developing affordable, over-the-counter CGM devices can expand market accessibility, especially in emerging economies. Integration with digital health platforms, including smartwatches and telemedicine services, can improve user engagement and remote monitoring. Additionally, forming partnerships with healthcare providers and insurers can facilitate wider adoption by ensuring reimbursement coverage and clinical validation.
Accuracy is evaluated by MARD, with?the latest generation of CGMs reporting 8–9% MARD, which is considered clinically trustworthy. Finger-sticks?are still just a little bit more accurate immediately, as interstitial fluid readings are behind blood glucose by several minutes.
Sometimes, while the sensor is warming up, if symptoms?are not matching what the sensor is reading, or when calibration is required. Most factory-calibrated CGMs (otherwise) don't require you to do routine finger sticks for?confirmation while using them daily.
Uninsured costs are approximately $70/month for the Libre 3, but can exceed $350/month for the Dexcom G7. (Coverage varies by country, insurance, and type of?diagnosis)
Ideal for type 1 diabetes, insulin-dependent type 2 diabetes, pregnant women with gestational diabetes, elderly with supportive caregivers and increasingly for healthy non-diabetic users interested in wellness and metabolism tracking.
Growing global burden of diabetes fuels the demand, 589 adults are living with it in whole world with large undiagnosed and prediabetic populations that increase the?addressable patient base across the hospital and homecare settings.
Real-time CGM (Dexcom G7) is continuously sending data?with alerts while intermittently scanned CGM (Libre) needs?to be scanned to see the readings, but newer models are now introducing optional real-time alarm functionalities.
Download Sample Report of Continuous Glucose Monitoring Device Market
Please fill out the form to request a customized copy of the research report.
